Corporate strategies and tactics for more effective drug development.
 | November 4, 2009
By:Bassil Dahiyat
As the first generation of biologics patents expire, companies are jokeying for position in follow-on biologics.
 |
October 14, 2009
By:Jerome Wilson, Martin Nemansky
Jerome Wilson and Martin Nemansky, explore some of the difficulties of implementing biomarkers during drug development.
|
 | October 2, 2009
By:Gen Li
How proper site activation and site enrollment can help you get the most from clinical trials.
|
July 22, 2009
By:Chris McKenna
The process of research and development of new drugs has become phenomenally expensive. Can Lean Six Sigma revitalize the innovation process for pharmaceutical companies?
|
July 22, 2009
By:Sarah Houlton
Statins should be given to people with high blood pressure or diabetes, even if they don?t have heart disease, according to a study published in the British Medical Journal.
|
 | July 1, 2009
Capitalize on the new age in healthcare with "disruptive innovation."
|
June 3, 2009
By:Walter Armstrong
Due to pharma's voluntary moratorium on doling out totefuls of freebies and all the lattes you can swallow, thousands of docs, researchers, and reporters had only their sleep-deprived selves to carry from data dump to data dump at this week?s American Society of Clinical Oncology (ASCO) annual confab in Orlando, Florida.
|
March 24, 2009
By:John Waslif, Jelena Markovic
Evidence-based medicine is fast becoming one of the key concepts in clinical and reimbursement practices in the developed world
|
| 
PharmExec Blog
Follow Us
RSS
Bookstore
What's the best managed pharma? Professor Bill Trombetta of Saint Joseph's University attempts to answer the question in Pharm Exec's Industry Audit.
The most respected annual ranking of top 50 pharmaceutical companies by prescription drug sales... Who's in, who's back, and who's out?
Super Reps book trilogy by Dr. Lou Sawaya MD, MBA
Don't miss this Podcast series commemorating the 20th anniversary of HBA's Woman of the Year Award with interviews spanning two decades of change makers.
Conducting clinical trials in emerging regions can give you the edge. Five Quintiles experts share their insights into navigating the global regulatory landscape.